We found that GZMB+ CD8+ T cells from the immune-rich type had a higher expression of CXCL13 (Fig. 4F and Fig. S5E), which was also reported to be associated with good responses to immunotherapies in triple-negative breast cancer [41]. The gene discussed is CD8A; the disease is triple-negative breast carcinoma.